Graves' disease is an autoimmune thyroid disease characterized by the presence of pathogenic autoantibodies to the TSH receptor (TSH-R). By using polymerase chain reaction, the extracellular region of the human TSH-R cDNA has been amplified and used to prepare recombinant TSH-R (extracellular) protein fused with glutathione-S-transferase (GST 
INTRODUCTION
Thyroid cell physiology is intimately regulated by the pituitary hormone, thyrotrophin (TSH) (Dumont, 1971) . The binding of TSH to its recep¬ tor on the thyroid cell leads to thyroid hormone synthesis and thyroid cell growth (Roger, Hotimsky, Moreau & Dumont, 1982) . In autoimmune thyroid disease in man, autoantibodies to the TSH receptor (TSH-R) are present which are pathogenic, leading to the hyperthyroidism of Graves' disease (Adams, 1980; Zakarija & McKenzie, 1987; Smith, McLachlan & Furmaniak, 1988) .
The recent cloning of the human TSH-R cDNA will allow its role in autoimmune thyroid disease to be ascertained. The primary structure of the human TSH-R comprises a single polypeptide of 764 resi¬ dues which, in common with all other G-binding protein receptors, traverses the membrane seven times (Libert, Lefort, Gerard et al. 1989; Nagayama, Kaufmann, Seto & Rapaport, 1989; Misrahi, Loosfelt, Atger et al. 1990) . Following the predicted signal sequence, 395 residues code for the extracellular part of the receptor, which is the likely region that interacts with the bulky glycoprotein hormone. This is also the region to which autoanti¬ bodies from autoimmune thyroid disease patients interact, since a proportion of these sera are known to inhibit the binding of TSH to its receptor (Zakarija & McKenzie, 1987) . The expression of the TSH-R cDNA as a recombinant protein in eukaryotic cells has shown that the receptor is biologically functional where it maintains reactivity with the hormone (Libert et al. 1989; Nagayama et al. 1989; Misrahi et al. 1990 ) and Graves' disease autoantibo¬ dies (Libert et al. 1989) . In this communication, we describe the expression and purification of the extracellular region of the TSH-R as a recombinant fusion protein in Escherichia coli (Banga, Barnett, Ewins et al. 1990a) . Although the receptor prep¬ aration prepared in E.coli fails to interact with TSH or receptor autoantibodies, the purified recombinant protein is suitable for immunological investigations to study its precise role in autoimmune thyroid disease. The work described has been presented in abstract form .
MATERIALS AND METHODS
Amplification by polymerase chain reaction (PCR) Poly(A)+ RNA (5 pg) prepared from Graves' thy¬ roid tissue, as already described (Huang, Page, Roberts et al. 1990 ), was used to synthesize firststrand cDNA using oligo d(T) priming with a commercial kit (Pharmacia Biotechnology, Milton Keynes, Bucks, U.K.). The 33 pi reaction volume was diluted to 1 ml in water and used directly for PCR. Oligonucleotides as primers for PCR were designed from the human TSH-R sequence (Nagayama et al. 1989) where the primers flanked the extracellular region of the cDNA coding for the human TSH-R. Additionally, the forward primer was designed to start from amino acid residue 20 following the signal sequence and both the forward and reverse primers incorporated a BamHI and EcoRI restriction site respectively which allowed the amplified cDNA product to be maintained in frame for expression in pGEX-2T (Banga et al. 1990a (RSR Ltd, Cardiff, S. Glamorgan, U.K.), lubrol was added to the pooled 50mM NaCl (pH 7.6) containing 1% (w/v) lubrol (Shrewring & Rees Smith, 1982 . Fifteen of these sera from the above panel have been described previously (Collison et al. 1990) . A pool of normal immunoglobulin from 20 individuals who were negative for cAMP-stimulatory activity was also used. Immunoblotting Immunoblotting was performed as already de¬ scribed (Banga et al. 1990a) using purified prep¬ arations of recombinant TSH-R (extracellular) (purified by preparative gel electrophoresis) and glutathione-S-transferase (GST). For immunoblot¬ ting, a rabbit antiserum to GST (dilution 1:500) was used to localize the recombinant fusion proteins. Sera from patients (dilution 1:50) or immunoglobu¬ lin preparations (0.2mg/ml) in haemoglobulin/ phosphate-buffered saline were also used followed by I-labelled protein A for immunoblotting. Some antibodies were subjected to absorption with TSH-R inclusion bodies to confirm authenticity of binding on the immunoblots (Banga et al. 1990a (Fig. 1, lane b) . Two different clones were fully sequenced in M13 and were identical to the pub¬ lished sequence (Nagayama et al. 1989 ) coding for the extracellular region of the receptor (not shown).
One of these cDNA clones was excised from M13 and religated into pGEX-2T. Southern blotting of a plasmid preparation from a colony grown overnight with 32P-labelled TSH-R(E) cDNA confirmed the transformation with the recombinant plasmid (Fig. 2) (Fig. 3, lanes 2 and 1 respectively) . However, the non-induced lysates also showed the presence of other bacterial proteins which co-mi¬ grate with the recombinant TSH-R (extracellular) fusion protein. Inclusion body preparations pre¬ pared from induced cultures (Fig-3 , lane 3) were extracted with 3 M urea to remove the bacterial proteins (Banga et al. 19906) (Fig. 3, lane 4) . Under these conditions, the recombinant fusion protein remains insoluble in the pellet (Fig. 3, lane 5 ). The recombinant protein purified by preparative gel electrophoresis is shown in Fig. 3 (lane 6 116, 97, 66, 45 and 29kDa. 5.25 and 5.39 containing proteins co-migrating at 72 kDa were visible together with a small number of lower molecular weight components (Fig. 3, lane 7) .
Immunoblotting
With anti-GST antibody The recombinant TSH-R (extracellular) fusion pro¬ tein and GST, both purified by ELFE, were subjected to immunoblotting with a rabbit antiserum to GST. Binding of the GST antibody to the fusion protein (Fig. 4, lane 3) confirmed that the purified material was a fusion protein with GST. The GST antibody binds GST at 26kDa (Fig. 4 and/or TSH-binding blocking activity (Collison et al. 1990 . Recombinant TSH-R (extracellu¬ lar) fusion protein, initially purified by preparative gel electrophoresis, was subjected to SDS-polyacrylamide gel electrophoresis for immunoblotting. GST, purified from non-recombinant pGEX-2T transfected E.coli, was also used in immunoblotting. No (Xie, Wang & Segaloff, 1990; Braun, Schofield & Sprengel, 1991; Ji & Ji, 1991) .
Although the purified recombinant TSH-R (extracellular) fusion protein produced in E.coli does not show any reactivity with its ligand or Graves' disease autoantibodies, it is suitable as a source of purified antigen for cellular investigations to study the role of T cells from patients with Graves' disease (Nicholson, Ewins, Huang et al. 1991 ) and production of monoclonal antibodies (G.C. Huang; unpublished observation). The abi¬ lity to use denatured recombinant protein to produce monoclonal antibodies which then show reactivity with native protein has been demonstrated pre¬ viously (Man, Cartwright, Morris et al. 1990 ). The availability of monoclonal antibodies to TSH-R will allow the purification of the recombinant receptor produced in eukaryotic systems (Page, 1988) by antibody affinity chromatography, as well as the analysis of the autoantigenic epitopes recognized by Graves' disease. 
